First-half sales rebounded at Roche.
And the Swiss drugmaker has virus testing kits to thank for the gains.
Overall sales rose 8% to almost $33.5 billion, beating forecasts.
But sales in the firm's diagnostics division rose by a half.
That more than compensated for a small decline for pharmaceuticals.
Roche is sticking to its forecasts for the year.
It sees sales and core profit both growing by low- to mid-single digit rates, and expects to increase its dividend.
Over the coming months the firm does expect sales of test kits to decline, though it says the outlook remains very uncertain.
But it says the pharmaceuticals division is now growing again, though some sectors, such as oncology, remain below pre-crisis levels.